Madelynne O. Willis

Feb 27, 2023 | nature.com | Madelynne O. Willis |Allison Hunt |Ahwan Pandey |Tamara Abulez |Sian Fereday |Dale W. Garsed | +10 more

AbstractHigh-grade serous ovarian cancer (HGSC) is frequently characterized by homologous recombination (HR) DNA repair deficiency and, while most such tumors are sensitive to initial treatment, acquired resistance is common. We undertook a multiomics approach to interrogate molecular diversity in end-stage disease, using multiple autopsy samples collected from 15 women with HR-deficient HGSC.

Feb 27, 2023 | go.nature.com | Madelynne O. Willis |Allison Hunt |Ahwan Pandey |Tamara Abulez |Sian Fereday |Dale W. Garsed | +10 more

AbstractHigh-grade serous ovarian cancer (HGSC) is frequently characterized by homologous recombination (HR) DNA repair deficiency and, while most such tumors are sensitive to initial treatment, acquired resistance is common. We undertook a multiomics approach to interrogate molecular diversity in end-stage disease, using multiple autopsy samples collected from 15 women with HR-deficient HGSC.